HPS Pharmacies wish to give notice that Seqirus Pty, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction for Ryaltris® nasal spray, as follows:
Ryaltris Nasal Spray
Olopatadine 600mcg + Mometasone furoate 25mcg/actuation
ARTG 312690
The following batches are affected by this notice:
| 240 Metered Dose Spray | 56 Metered Dose Spray |
|
|
This defect correction was initiated due to a technical labelling issue. The batch number and expiry date on the affected batches can be smudged or blurred upon contact with an alcohol-based solvent.
Seqirus advises customers to:
- Ensure that alcohol-based sanitisers or wipes do not come into contact with the bottle label; and
- Retain the carton for the duration of use to maintain a durable record of the batch number and expiry details.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Seqirus on 1800 008 275 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates